Caelyx®: Phase II studies in ovarian cancer

European Journal of Cancer

Volumn 37, Issue SUPPL. 9, 2001, Pages 8-14

  Johnston, S R D ^a   Gore, M E ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Caelyx; Chemotherapy; Ovarian cancer; Platinum refractory

Indexed keywords

ANTHRACYCLINE; DOXORUBICIN; LIPOSOME; PACLITAXEL; PLATINUM; TOPOTECAN; ANTINEOPLASTIC AGENT;

ADVANCED CANCER; ALOPECIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG TARGETING; DYSESTHESIA; ENCAPSULATION; HUMAN; NEUTROPENIA; OVARY CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; TREATMENT FAILURE; TREATMENT OUTCOME; DRUG DESIGN; FEMALE; OVARY TUMOR; REVIEW;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE II; DOXORUBICIN; DRUG DESIGN; FEMALE; HUMAN; LIPOSOMES; OVARIAN NEOPLASMS; TREATMENT OUTCOME;

EID: 0035669577     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0959-8049(01)00329-x     Document Type: Article

References (31)

1. Cancer statistics, 1999
2. Carboplatin reinduction after taxane in patients with platinum-refractory epithelial ovarian cancer
3. Taxol: A unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms
4. Phase II trial of oral altretamine for relapsed ovarian carcinoma: Evaluation of defining response by serum CA125
5. Topotecan for the treatment of advanced epithelial ovarian cancer; an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel
6. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with Stage III and Stage IV ovarian cancer
7. Updated analysis shows a highly significant improved overall survival for cisplatin-paclitaxel as first-line treatment of advanced ovarian cancer; mature results of the EORTC-GCCG, NOCOVA, NCICCTG and Scottish Intergroup trial
8. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum sensitive ovarian carcinoma: A Gynaecologic Oncology Group study
9. Activity of gemcitabine inpatients with advanced ovarian cancer; responses seen following platinum and paclitaxel
10. The role of anthracyclines in epithelial ovarian cancer
11. Impact of doxorubicin on survival in advanced ovarian cancer
12. Ovarian Cancer Meta-Analysis Project. Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma; a meta-analysis
13. A phase I clinical trial and pharmacokinetic evaluation of liposome encapsulated doxorubicin
14. Prolongation of the circulation time of doxorubicin encapsulated in liposomes containing a polyethylene-glycol-derivatized phospholipid: Pharmacokinetic studies in rodents and dogs
15. Pharmacokinetics, biodistribution, and therapeutic efficacy of doxorubicin encapsulated in STEALTH® liposomes (DOXIL®)
16. Sterically stabilized liposomes: Improvements in pharmacokinetics and antitumor therapeutic efficacy
17. Identification and characterisation of the blood vessels of solid tumours that are leaky to circulating macromolecules
18. Use of liposomes as injectable drug delivery systems
19. Pharmacokinetics and therapeutics of sterically stabilized liposomes in mice bearing C-26 colon carcinoma
20. Arrest of human lung tumour xenograft growth in severe combined immunodeficient mice using doxorubicin encapsulated in sterically stabilized liposomes
21. Doxorubicin encapsulated in sterically stabilized liposomes for the treatment of a brain tumor model: Biodistribution and therapeutic efficacy
22. Stealth liposomal doxorubicin (Doxil) delivers more doxorubicin to AIDS-Kaposi's sarcoma lesions than to normal skin
23. Prevention of chronic doxorubicin cadiotoxicity in Beagles by liposomal encapsulation
24. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes
25. Salvage chemotherapy for epithelial ovarian carcinoma
26. Clinical efficacy and prospects for use of pegylated liposomal doxorubicin in the treatment of ovarian and breast cancers
27. Liposomal doxorubicin (Doxil); antitumour activity and unique toxicities during two complementary phase I studies
28. Phase II study of liposomal doxorubicin in refractory ovarian cancer: Antitumor activity and toxicity modification by liposomal encapsulation
29. Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer
30. Treatment of patients with ovarian carcinoma with pegylated liposomal doxorubicin
31. Topotecan for the treatment of recurrent epithelial ovarian cancer